1.. Introduction {#S0001}
================

Inflammation is the reaction of vascularized tissue to local injury. The causes of inflammation are many and varied. Inflammation may occur in response to trauma, chemical or physical injury, autoimmune responses and infectious agents, but also in response to physiological conditions, such as diet and exercise [\[1,2\]](#CIT0001 CIT0002). Inflammation is an important component of innate immunity and necessary for priming adaptive immunity, but is also crucial for the effector phase of the immune response. Soluble mediators, such as chemokines, are shown to play an important role in driving the various components of inflammation, especially leukocyte influx. They may originate from plasma-derived systems, such as complement and kinins, from recruited or tissue-resident cells or released as a direct consequence of tissue damage [\[3,4\]](#CIT0003 CIT0004).

The chemokine system in mammals is complex and comprises around 50 ligands, which are constitutively expressed or induced by inflammatory stimuli, and 20 G protein-coupled receptors (GPCRs) or seven transmembrane receptors [\[5,6\]](#CIT0005 CIT0006). In this article, the properties of C--C chemokine ligand 5 (CCL5), also known as regulated upon activation, normal T cell expressed and secreted (RANTES), one of the members of the mammalian chemokine system will be explored. Chemokines bind to their receptors which are expressed on many cell types, including leukocytes, endothelial cells, fibroblasts, epithelial, smooth muscle and parenchymal cells. The interaction between chemokines and their receptors is said to be promiscuous in the sense that several receptors interact with multiple ligands and several ligands interact with more than one receptor. It has been previously argued that this complexity of the system is important for the many actions of chemokine system but is not absolute. Some chemokine--chemokine receptor interactions are not functionally redundant and can potentially be targeted by drugs that block the receptor or interfere with the function of the ligand [\[5\]](#CIT0005). Chemokines play an important role in leukocyte biology, by controlling cell recruitment and activation in basal and in inflammatory circumstances. In addition, because chemokine receptors are expressed on other cell types, chemokines have multiple other roles, including angiogenesis, tissue and vascular remodeling, pathogen elimination, antigen presentation, leukocyte activation and survival, chronic inflammation, tissue repair/healing, fibrosis, embryogenesis and tumorigenesis [\[5,7\]](#CIT0005 CIT0007).

1.1. CCL5/RANTES {#S0001-S2001}
----------------

The *ccl5* gene was discovered in 1988 [\[8\]](#CIT0008), and this was followed by the isolation and first characterization of the protein in 1990 [\[9\]](#CIT0009). Chemokines are structurally related and grouped according to the relative position of conserved cysteine residues, along with the respective receptors. CCL5/RANTES belong to the C--C chemokine subfamily, whose chemokines present adjacent cysteines, and comprises the majority of the chemokines [\[6,10\]](#CIT0006 CIT0010). To facilitate reading, the chemokine will be referred to as CCL5 from now on.

CCL5 has been shown to induce the *in vitro* migration and recruitment of T cells, dendritic cells, eosinophils, NK cells, mast cells and basophils. Although initially considered to be a T cell-specific cytokine (hence the original name, RANTES) [\[8\]](#CIT0008), CCL5 is produced by platelets, macrophages, eosinophils, fibroblasts, endothelium, epithelial and endometrial cells. The variety of cells that express and mediate CCL5 effects implicates this chemokine in multiple biological processes, from pathogen control to enhancement of inflammation in several 'sterile\' disorders, such as cancer and atherosclerosis [\[11\]](#CIT0011). The current tools available for the study of CCL5 are listed in [Table 1](#T0001).
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**Tools to study CCL5.**

  **Tool (Developing company)**                                            **Definition and first description**
  ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------
  **Deficient mice**                                                        
  CCL5^-/-^                                                                Disruption of CCL5 expression, Makino *et al.*[\[12\]](#CIT0012)
  CCR1^-/-^                                                                Disruption of CCR1 expression, Gao *et al.*[\[13\]](#CIT0013)
  CCR3^-/-^                                                                Disruption of CCR3 expression, Humbles *et al.*[\[14\]](#CIT0014)
  CCR5^-/-^                                                                Disruption of CCR5 expression, Zhou *et al.*[\[15\]](#CIT0015)
  **Modified chemokines**                                                   
  Recombinant CCL5/RANTES (different suppliers)                            Human, mouse and rat CCL5, expressed in bacteria
  Aminooxypentane (AOP)-RANTES (Merck Serono) (also PSC- and NNY-RANTES)   N-terminal chemically modified CCL5 with antagonistic activity, Simmons *et al.*[\[16\]](#CIT0016)
  Methionine (Met)-RANTES (Merck Serono)                                   CCL5 with retention of N-terminal methionine gained antagonistic activity, Proudfoot *et al.*[\[17\]](#CIT0017)
  \[^44^AANA^47^\]-RANTES                                                  CCL5 mutated at GAG binding site, impairs CCL5 oligomerization and function *in vivo*, Johnson *et al.*[\[18\]](#CIT0018)
  \[E66A\]-RANTES                                                          CCL5 mutated in oligomerization site, impairs CCL5 function *in vivo*, Baltus *et al.*[\[19\]](#CIT0019)
  MKEY                                                                     Peptide inhibitor of CCL5/CXCL4 hetero dimerization, Iida *et al.*[\[20\]](#CIT0020)
  **Small-molecule inhibitors**                                             
  TAK 220/779 (Takeda Chemical Industries)                                 CCR5 antagonists, Imamura *et al.*[\[21\]](#CIT0021) and Baba *et al.*[\[22\]](#CIT0022)
  Maraviroc (Pfizer, Inc)                                                  CCR5 antagonist, Fätkenheuer *et al.*[\[23\]](#CIT0023)
  SCH-C (Schering Plough)                                                  CCR5 antagonist, Strizki *et al.*[\[24\]](#CIT0024)
  Vicriviroc (Schering Plough)                                             CCR5 antagonist, Strizki *et al.*[\[25\]](#CIT0025)
  YM-344031 (Astellas)                                                     CCR3 antagonist, Suzuki *et al.*[\[26\]](#CIT0026)
  UCB 35625 (Banyu Pharmaceutical)                                         CCR1/CCR3 antagonist, Sabroe *et al.*[\[27\]](#CIT0027)
  CCX721/ CCX354 (Chemo Centryx)                                           CCR1 antagonists, Dairaghi *et al.*[\[28,29\]](#CIT0028 CIT0029)
  BX471 (Berlex Biosciences)                                               CCR1 antagonist, Horuk *et al.*[\[30\]](#CIT0030)
  MLN3897 (Millennium)                                                     CCR1 antagonist, Vallet *et al.*[\[31\]](#CIT0031)
  AZD4818                                                                  CCR1 antagonist, Kerstjens *et al.*[\[32\]](#CIT0032)
  CP-481715                                                                CCR1 antagonist, Gladue *et al.*[\[33\]](#CIT0033)
  Neutralizing antibodies                                                   
  Anti-CCL5 (different companies)                                          Rat, mouse and human monoclonal and polyclonal antibodies
  MAb d5d7 (VLST corporation)                                              Targets human CCL3, CCL4 and CCL5, Scalley-Kim *et al.*[\[34\]](#CIT0034)
  Nanobodies                                                               Single domain camelid antibody fragment against CCL5, Blanchetot *et al.*[\[35\]](#CIT0035)
  CCL5-binding proteins                                                     
  Evasin 4                                                                 CCL5/CCL11-binding protein, Déruaz *et al.*[\[36\]](#CIT0036)
  M3 -- Murine γ herpesvirus chemokine binding protein                     Soluble, promiscuous binding protein, Parry *et al.*[\[37\]](#CIT0037)
  vCCI, 35K -- viral CC chemokine inhibitor                                Poxvirus-encoded soluble receptors, Smith *et al.*[\[38\]](#CIT0038)
  M-T7 -- mixoma virus T7 protein                                          IFN-γ/chemokine-binding protein, Lalani *et al.*[\[39\]](#CIT0039)
  Miscelaneous                                                              
  Immunization                                                             Naked DNA vaccination inducing anti-CCL5 antibodies in rodents, Youssef *et al.*[\[40\]](#CIT0040)

**Abbreviations**: Inf: infection; SLE: Systemic lupus erythematosus; RA: Rheumatoid arthritis; RSV: Respiratory syncytial virus; MS: Multiple sclerosis; GVHD: Graft versus host disease; HIV: Human immunodeficiency virus; LCMV: lymphocytic choriomeningitis virus; COPD: Chronic obstructive pulmonary disease; HSV: Herpes simplex virus; EAE: Experimental autoimmune encephalomyelitis; SIV: Simian immunodeficiency vírus.

Description of the tools (animals, antibodies, modified chemokines, small molecules and chemokine-binding proteins) used for the study of CCL5 and its receptors in different experimental settings.

The many biologic effects of chemokines are mediated by their interaction with chemokine receptors on the cell surface. The most relevant known receptors for CCL5 are CCR1, CCR3 and CCR5 [\[6\]](#CIT0006). [Figure 1](#F0001) depicts the interactions of CCL5 with its receptors and also the other known chemokine ligands that bind to CCR1, CCR3 and CCR5. The affinity of CCL5 binding to its receptors is variable, with greater affinity for CCR5 and CCR1, and binding CCR3 with less affinity [\[41\]](#CIT0041). For the process of cell recruitment *in vivo*, CCL5 oligomers are immobilized on endothelial glycosaminoglycans (GAGs) and interact with the receptors expressed by incoming leukocytes in the blood vessels. Oligomerization is not essential for CCL5 activity *in vitro*, but has been demonstrated to be crucial for *in vivo* activity, as well as GAG binding [\[42\]](#CIT0042). CCL5 heterodimerization with CXCL4 enhances CCL5 biological functions [\[43\]](#CIT0043). For example, CXCL4 may amplify CCL5-dependent monocyte arrest on the endothelium [\[44\]](#CIT0044). In their turn, chemokine receptors are fully functional as monomers but also form homo or heterodimers, which allow for new properties such as receptor cointernalization, cross-desensitization and differential signaling [\[45\]](#CIT0045) ([Figure 1](#F0001)).

![**CCL5 biology.** The chemokine receptors for CCL5 and common shared agonists for these receptors are illustrated. Chemokine receptor activation has major effects on leukocyte and nonleukocyte populations. Such biological effects may be modulated by the action of nonfunctional (CCR5Δ32) or decoy receptors (D6 and DARC), by chemokine receptor homo- and heterodimerization, or by a combination of both.](IETT_A_837886_F0001_B){#F0001}

CCL5 oligomers interact with the receptors at the three extracellular loops and the aminoterminal portion [\[10\]](#CIT0010). The formation of the ligand--receptor complex causes a conformational change in the receptor that activates the subunits Gα~i~ and Gβγ of the G-protein, leading to an increase in levels of cyclic AMP, inositol triphosphate and intracellular calcium [\[7\]](#CIT0007). These signaling events cause cell polarization and translocation of NF-κB, which results in the increase of phagocytic ability, cell survival and transcription of proinflammatory genes, many of which are chemokines and chemokine receptors [\[10,46\]](#CIT0010 CIT0046). CCL5 is also able to induce G protein-independent signaling. Once G protein-dependent signaling occurs, the CCL5-receptor complex is internalized via chlatrin-mediated endocytosis associated to the adapter molecules Adaptin-2 and β-arrestin. Cytoplasmic organelles and vacuoles are recruited to perform the recycling of receptors, and/or degradation of active chemokine--receptor complexes. These effects are important to regulate receptor levels at the external membrane, allowing for regulation of the cellular activity and reduction of extracellular levels of CCL5 and other chemokines, important to maintain homeostasis [\[47,48\]](#CIT0047 CIT0048).

The chemokine system also features a group of atypical receptors, which binds CCL5 and does not trigger usual signaling events after interaction, due to uncoupling of the signaling machinery. Unlike other chemokine receptors, the main role of these decoy receptors appears to be the sequestering of ligands, therefore functioning as chemokine scavengers. The best known examples of decoy-receptors that bind CCL5 are DARC [\[49\]](#CIT0049) and D6 ([Figure 1](#F0001)) [\[49,50\]](#CIT0049 CIT0050).

In the following topics, experimental studies that have investigated the role of CCL5 in various diseases will be described.

2.. CCL5 in viral infections {#S0002}
============================

The recognition of pathogenic viruses by the immune system, mostly through engagement of pattern recognition receptors, leads to early production of cytokines. Those include interferons (IFNs), essential for the antiviral response, and proinflammatory mediators, most notably CC chemokines. CCL5 is an early expressed chemokine that can also be induced by TNF-α and IFN-γ at later stages of infection [\[51\]](#CIT0051). Among all chemokines, CCL5 and CCL3 are particularly associated with viral infections [\[52\]](#CIT0052). CCL5 is released by degranulation from activated virus-specific CD8^+^ T cells in parallel with granzyme A and perforin [\[53\]](#CIT0053). CCL5 is also produced by CD4^+^ T lymphocytes, epithelial cells, fibroblasts and platelets [\[54\]](#CIT0054). Several cell types activated by CCL5 are directly involved in antiviral response, including NK cells, T CD4^+^ lymphocytes, monocytes, mast cells and dendritic cells [\[55\]](#CIT0055).

Separately, and certainly a hallmark on the studies of chemokines in viral infections, is the discovery that CCL5 and other chemokines were natural inhibitors of human immunodeficiency virus (HIV) infection. A few months after this discovery, in 1995, it was found that CCR5 was a coreceptor for HIV [\[56\]](#CIT0056). Interestingly, human subjects carrying a CCR5 gene variant with a 32 bp deletion in the coding region, named the CCR5Δ32 allele, are resistant to HIV infection and progression of disease. The deletion renders CCR5 defective, and results in impaired viral entry in macrophages, one of the target cells for HIV [\[57\]](#CIT0057). Thus, pharmacological blockade of CCR5 was employed as a strategy to treat and prevent HIV infections, resulting in a research boost on the chemokine system and in the development of several inhibitors and antagonists for CCR5 and its ligands [\[58\]](#CIT0058). The roles of CCL5 in the context of HIV infection include boosting of T cell responses [\[55\]](#CIT0055), and direct inhibition [\[59\]](#CIT0059) or enhancement of infection [\[54\]](#CIT0054). Effects of CCL5 in HIV infection vary due to the concentration of CCL5 *in situ*, as low concentrations activate GPCR-dependent pathways and high concentrations triggers CCL5 aggregation and subsequent G-protein-independent signaling events. GPCR activation by CCL5 inhibits HIV/CCR5 interaction and suppresses HIV infection. Conversely, G protein-independent pathways do not involve CCL5 and HIV competing for the receptor, causes excessive activation of signaling effectors that culminates in cell activation and enhancement of HIV infection [\[54\]](#CIT0054). The variety of host tissues affected by viruses, added to different contexts of chronic or acute infection, makes it difficult to define a role for CCL5 in viral infections. Instead, the effects of CCL5 are categorized according to the site of infection/disease and viral tropism.

2.1. Respiratory tract infections {#S0002-S2001}
---------------------------------

The production of CCL5 has been observed in most viral infections of the respiratory tract. These include infections by hantavirus, reovirus, adenovirus, coxsackie virus, rhinovirus, respiratory syncytial virus (RSV) and the well-known coronavirus and influenza virus. A unifying feature of pathogenic respiratory tract viruses is that many possess an RNA genome. Some studies have pointed that double-stranded RNA, an intermediate form in viral genome replication, activates TLR3 [\[60\]](#CIT0060) and contributes to eosinophilic inflammation in the airways, mediated by CCL5 and CCL11, which may aggravate chronic diseases such as asthma. For example, it has been shown that hantaviruses, which may cause life-threatening hemorrhagic or cardiopulmonary syndromes, induce CCL5 *in vitro* in several cell types and in infected patients [\[61\]](#CIT0061). Early CCL5 expression is commonly triggered by nonpathogenic hantaviruses, such as Prospect Hill virus, while pathogenic viruses evade immune detection and delay CCL5 production, which is the case for Hantaan virus. CCL5 is believed to play a role in the initial control of viral replication, which would prevent prolonged proinflammatory responses that likely contribute to disease pathogenesis [\[61\]](#CIT0061).

RSV is a common etiologic agent of lower respiratory tract infection in infants, inducing obstructive lung diseases and bronchial asthma [\[62\]](#CIT0062). Children with RSV infections have increased CCL5 levels in airway secretions and CCL5 expression at the upper airway correlates positively with disease severity. Using a murine model of RSV infection, Culley *et al.* found that CCL5 expression occurs in two phases: the first as a consequence of the innate response by resident lung cells, and the second derived from CD4^+^ and CD8^+^ T cells. Treatment with Met-RANTES, a functional inhibitor of CCL5, at the second phase of CCL5 production reduced immunopathology, suggesting that CCL5 receptors play a central role in driving inflammation in RSV lung disease. However, chemokine blockade during the first phase showed opposite effects, which makes it difficult to anticipate what would be the effects of targeting this pathway in clinical studies [\[63\]](#CIT0063).

Severe acute respiratory syndrome (SARS) is an acute life-threatening respiratory illness that differs in severity from other coronavirus infections. Elevated serum levels of chemokines in SARS patients suggest that SARS pathogenesis may be due to immune dysregulation. Law *et al.* found that the nsp1 protein of SARS coronavirus was a strong inducer of CCL5 in human lung epithelial cells, in contrast to nsp1 proteins from nonpathogenic coronaviruses. In another study of acute respiratory infection, combined treatment with antivirals and CCR1 blockade resulted in increased survival in pneumovirus-infected mice [\[64\]](#CIT0064). These findings corroborate the idea that (SARS) pathogenesis, and similar respiratory syndromes, have a strong immune/inflammatory component that can be targeted through CCL5 intervention [\[52,65\]](#CIT0052 CIT0065).

Finally, CCL5 was shown to be involved in influenza virus infections. *In vitro* infection of human alveolar macrophages with the H1N1 PR/8 strain showed a 234-fold increase in CCL5 mRNA expression [\[66\]](#CIT0066). Also, studies demonstrated that CCL5 is elevated in the lungs of H5N1-infected patients [\[67\]](#CIT0067). Interestingly, a comparative analysis of a seasonal Influenza strain and the H1N1 pandemic strain revealed that the pandemic strain induced greater levels of CCL3 and CCL5 in human macrophages. This was related to the ability of the pandemic strain to suppress SOCS-1 and RIG-I expression, which resulted in elevated chemokine levels that could contribute to the cytokine storm presented by severe flu patients [\[68\]](#CIT0068). To evaluate the role of CCL5 in influenza and paramyxovirus infections, Tyner *et al.* infected CCL5- and CCR5-deficient mice and demonstrated that the CCL5-CCR5 axis provided antiapoptotic signals to virus-infected macrophages. Usually, apoptosis of infected cells would be helpful for the host, but the enhanced apoptosis of infected macrophages deprived of CCL5-CCR5 signaling reduced the clearance of viruses and infected cell debris, which contributed to tissue damage. Thus, activation of CCR5 by CCL5 is important to extend macrophage survival and control infection [\[69\]](#CIT0069).

2.2. Neurotropic infections {#S0002-S2002}
---------------------------

Neuroinflammation, or inflammation in the central nervous system (CNS), must be carefully regulated to avoid immune-mediated neuronal death. CCL5 is induced in several models of viral CNS infection [\[70,71\]](#CIT0070 CIT0071), and participates in the activation of microglia and in the recruitment of T lymphocytes and NK cells, that could either result in pathogenesis or viral clearance [\[72\]](#CIT0072). Astrocytes are able to secrete CCL5 when exposed to the dsRNA analogue poly I:C, but not when exposed to other PRR ligands [\[73\]](#CIT0073). CCL5 production by astrocytes was shown to contribute to pathogenesis in the infection by Borna disease virus, which does not cause neuronal death directly. In fact, neuronal degeneration was mediated by microglia, when activated by astrocyte-derived CCL5 [\[74\]](#CIT0074). In a murine model of lymphocytic choriomeningitis virus, it is known that IFN-γ-producing T CD4^+^ cells mediate pathogenesis in the CNS. Further investigation by Lin *et al.* demonstrated that IFN-γ induced the production of CCL5 (and other proinflammatory chemokines) by microglia/macrophages, which enhances neuroinflammation and culminates in mice weight loss [\[75\]](#CIT0075). Rabies virus (RV) induces CCL5 production by microglia during replication, through p38-NFκB activation [\[76\]](#CIT0076). This induction is controlled by the protein N of RV pathogenic strains, which prevents RIG-I activation and further CCL5 production, leading to disease and lethality in infected mice [\[77\]](#CIT0077). In contrast, Zhao *et al.* infected mice with a genetically modified RV strain that overexpresses CCL5, for the purpose of vaccination, and found that this strain caused extensive neuroinflammation, culminating in neurological disease and mice death, thus confirming the major role that CCL5 play in leukocyte recruitment to the CNS [\[78\]](#CIT0078).

Besides a deleterious proinflammatory role that CCL5 could play in CNS, this chemokine is protective against RV and against other viruses. A well-studied example involves acute infection by West Nile virus (WNV) in mice, in which the lack of CCR5 leads to decreased leukocyte recruitment, increased viral load in the CNS and enhanced mortality. WNV infection induces high and continuous levels of CCL5, which is required for the local accumulation of NK cells, macrophages and T lymphocytes to control infection [\[79\]](#CIT0079). In agreement with these findings, epidemiological studies found that humans possessing the CCR532 allele are more prone to symptomatic infection by WNV, due to a defective CCR5/CCL5-axis. Similar observations were made for Tick-borne encephalitis virus, which indicates that CCL5-mediated cell recruitment could be a common mechanism of resistance to neurotropic flaviviruses [\[80,81\]](#CIT0080 CIT0081).

Among herpes viruses, herpes simplex viruses (HSV-1, -2) are neurotropic viruses that cause encephalitis in newborns and immunocompromised humans. CCL5 was shown to be produced during herpetic encephalitis in mice and mediate T cell recruitment to the CNS [\[82\]](#CIT0082). Other reports demonstrate that CCL5 is upregulated in latently infected trigeminal ganglia, a major feature of HSV-1 infection, which results in the retention of T lymphocytes in neurons of both mice and humans and prevents viral reactivation [\[83\]](#CIT0083).

Large DNA viruses, such as herpes viruses, present a high level of adaptation to the human host and are known to cause latent infections. Under immune suppressive conditions, herpes viruses may reactivate and cause neurological disease. Latency is possible due to the ability of the virus to evade immune surveillance, commonly blocking the effect of CCL5 and other proinflammatory chemokines [\[84\]](#CIT0084). Human herpes virus (HHV)-8 blocking strategies for chemokines are many and includes a viral chemokine that antagonizes CCR3 and CCR5 [\[85\]](#CIT0085), the viral chemokine-binding protein M3 that binds to all chemokines at nanomolar affinities, and a HHV-8-encoded GPCR that induces cell proliferation [\[86\]](#CIT0086). The human cytomegalovirus (HCMV) is particularly dedicated to control CCL5 biologic functions, as it encodes a micro-RNA that downregulates CCL5 expression [\[87\]](#CIT0087) and a chemokine-binding protein that binds to CCL5 at picomolar rates and prevent interactions with host chemokine receptors [\[88\]](#CIT0088). This indicates that CCL5 is an important mediator for the control of HCMV infections.

2.3. Liver infections {#S0002-S2003}
---------------------

Infectious liver diseases are a major threat to human health. Hepatitis C virus (HCV) infection causes chronic hepatic inflammation with risk of developing cirrhosis and hepatocellular carcinoma. Polymorphisms in *ccl5* gene showed that CCL5 is protective in hepatitis C, since a mutation in the -403 position that increases CCL5 expression resulted in reduced portal inflammation and milder fibrosis. Conversely, patients that carry the CCR532 allele also have reduced inflammation and fibrosis, which indicates that the CCL5-CCR5 pathway could play a role in disease pathogenesis [\[89\]](#CIT0089). Another study with hepatitis B virus (HBV) found similar results, where the combination of the -403 CCL5 and CCR532 polymorphisms was associated with recovery from HBV infection [\[90\]](#CIT0090).

The yellow fever virus (YFV) is the causative agent of a hemorrhagic fever with characteristic clinical presentations due to severe liver injury, hence the name 'yellow fever\' [\[91\]](#CIT0091). YFV infections have been successfully controlled through vaccination with an attenuated live strain, though a small percentage of vaccinees develop yellow fever. A study by Pulendran *et al.* described a unique YFV vaccine-associated viscerotropic disease patient, which presented persistent viremia; robust activation of T and B lymphocytes; and a 200-fold increase in the number of CD14^+^CD16^+^ circulating monocytes. Those observations were associated to the genetic background of the patient, who was heterozygous for the -403 CCL5 and CCR532 gene variants, leading to the aberrant immune response to YFV vaccination [\[92\]](#CIT0092). Dengue virus (DENV) is closely related to YFV and causes a similar hemorrhagic fever, which emerged as a major world health problem in the past decades. Recent findings on dengue confirmed that DENV infection damages the liver, due to the elevation of serum transaminase levels in severe disease patients [\[93\]](#CIT0093). Histological analysis of liver sections from dengue fatal cases show lymphocytes, Kupfer cells and sinusoidal endothelium positively stained for CCL5, which correlates with increased hepatic CCL5 levels observed in acute dengue patients [\[94\]](#CIT0094). This increase in hepatic CCL5 due to DENV infection could mediate leukocyte recruitment to the organ and contribute to the systemic inflammation that culminates in the hemorrhagic phenomena. CCL5 production was also described in a dengue model in mice, where CCL5 levels were concomitant with liver injury. However, it is not known if CCL5 contributes to injury or is produced as a consequence of tissue damage in dengue [\[95\]](#CIT0095).

In conclusion, in the context of respiratory and neurotropic viral infections, it seems that CCL5 production presents a dual role. CCL5 is necessary to control certain viral infection, including influenza, RSV, RV, HSV and WNV. The antiviral role of CCL5 is evident in HHV-8 and HCMV infections, where immune evasion mechanisms targeting CCL5 are essential and actively employed by these viruses. However, CCL5 seems to be deleterious in later phases of infection, where it contributes to excessive inflammation and tissue damage in all the diseases addressed in this section. Thus, conceptually, it would be ideal to block CCL5 in later phases of infection, where immunopathology is the main component of respiratory or neurotropic diseases, rather than the virus itself. The role of CCL5 in liver infections is not as clear, especially because beneficial or detrimental effects of CCL5 are dependent on the chemokine receptor engaged and whether the infection is chronic (viral hepatitis) or acute (YFV and DENV). However, CCL5-mediated inflammation is a common feature of these infections in later phases, which contributes to fibrosis or to hemorrhagic manifestations depending on the infection. Therefore, any potential blockade of CCL5 or its receptors in the context of viral infections could only be employed at the later stages of disease in order to prevent immunopathology. Earlier treatment could have deleterious effects on the capacity of the host to deal with the viral infection. As separating early (viral-mediated) and late (immune-mediated) phases of disease after viral infection may be very problematic in the clinical context, it is not likely that strategies aimed at blocking CCL5 or its receptors may be useful in patients. The clear exception is HIV as in this case blockade of CCR5 is associated with decreased viral entry. Blocking CCL5 in the context of HIV is unlikely to achieve similar benefits.

3.. Helminth infection {#S0003}
======================

Infections by *S. mansoni* may evolve to chronic illness with fibrotic liver injury, characterized by the formation of granulomas around parasite eggs. In a study by Souza *et al.*, liver granulomas of chronically infected CCR5^--/--^ mice showed more cells and greater collagen deposition in comparison with WT mice, which was associated with higher levels of IL-5, IL-13, CCL3 and CCL5. Therefore, CCR5 abrogation was deleterious during experimental *S. mansoni* infection, due to enhanced fibrosis and granulomatous inflammation [\[96\]](#CIT0096). Among different consequences of *S. mansoni* infection, periportal fibrosis of the liver is a serious event that involves remodeling of the extracellular matrix and excessive deposition of collagen, primarily by hepatic stellate cells. Booth *et al.* demonstrated that a high TNF-α concentration in adult men was the single risk factor for *S. mansoni*-induced node size, but low TNF-α levels were not protective if the patient also expressed low CCL5 levels [\[97\]](#CIT0097). A comprehensive analysis of chemokine expression in a mouse model of *S. mansoni* infection showed that CCL5 levels were higher where the T~h~1 response was enhanced, for example by administration of IL-12 in combination with egg antigen [\[98\]](#CIT0098). This study was in accordance with other reports stating that CCL5 was protective in *S. mansoni* infection, and suggested that high levels of CCL5 resulted in reduced granulomas. In addition, Chensue *et al.*\'s study on pulmonary granulomas elicited with antigens of *S. mansoni* showed that CCL5 played different roles on granuloma formation. Specifically, CCL5 contributed to a T~h~1-biased inflammation and limited the T~h~2 response, analogous to the effect of IFN-γ in the polarization of immune responses. These findings suggest that CCL5 is an important regulatory molecule that plays distinct roles in T~h~1- and T~h~2-driven inflammatory responses in schistosomiasis [\[99\]](#CIT0099).

However, in different contexts, after genetic ablation of CCR5, CCL5 has been shown to efficiently bind to CCR1 and promote NK cell recruitment and activation in a T cell mediated hepatitis model [\[100\]](#CIT0100). Thus, the increased binding of CCL5 to CCR1 upon blockade or deletion of CCR5 would be an additional aspect to explain the discrepancy between CCL5 and CCR5 neutralizing strategies in different disease contexts. This aspect should therefore be taken into account when designing therapeutic strategies and assigning specific roles to CCL5.

Overall, it appears that infected mice or patients with schistosomiasis, which present a mild form of disease, develop an adaptive immune response with greater activation of CCR5 over CCR1. Conversely, severe forms of disease associate with increased activation of CCR1 over CCR5. CCR1 activation would be predominantly mediated by CCL3, while CCR5 activation would be predominantly mediated by CCL5 [\[96\]](#CIT0096). Despite sharing nearly identical receptor affinities, the specificity of CCL3 and CCL5 are well defined, and result in opposing activities regarding the clinical presentation of disease. CCL5 is evidently protective in schistosomiasis. The T~h~2-biased immune response developed against helminthes is pathogenic, contributing to the generation and maintenance of granulomas. Thus, any potential pharmacological drug development should prioritize CCL5 activity through CCR5 in order to prevent immunopathology. As CCL5 administration to patients is likely to cause unwanted effects, blockade of CCR1 in addition to antischistosomal drugs could be of potential value in patients with the most severe diseases.

4.. Asthma {#S0004}
==========

Allergic inflammatory diseases usually develop in tissues that present large epithelial surface areas, such as the lung, skin and gut. To understand how tissue-specific memory and inflammation-specific T cell trafficking facilitates the development of allergic disease would be of great therapeutic interest [\[101\]](#CIT0101). In animal models of acute allergic inflammation, cytokines and chemokines such as IL-4, IL-5, IL-9, IL-13, CCL5 and CCL11 have been shown to induce eosinophilic airway inflammation, antigen-specific IgE production, and airway hyperresponsiveness [\[102\]](#CIT0102). CCL5 has been identified in the airways of asthmatic patients, where it induces eosinophil recruitment through the CCR3 receptor [\[103\]](#CIT0103). Airway inflammation and cytokines/chemokines production are important markers of asthma, but the asthmatic response is complex and difficult to transpose to experimental models [\[104\]](#CIT0104).

CCL5 mediates eosinophil, neutrophil and monocyte recruitment to the airways [\[9,105\]](#CIT0009 CIT0105) and initiates important events in the inflammatory response such as integrin activation, lipid mediator biosynthesis and degranulation [\[106\]](#CIT0106). CCL5 is constitutively expressed in the lungs and in the bronchoalveolar fluid of patients with asthma [\[107\]](#CIT0107). Several *in vivo* studies have described the CCL5-dependent recruitment of eosinophils during allergic airway inflammation, where treatment with met-RANTES decreased eosinophilia after antigen challenge [\[108\]](#CIT0108). Regarding the contribution of CCL5 to the development of airway hyperresponsiveness (AHR), Koya *et al.* reported that after repeated allergen challenge in sensitized mice, CCL5 is upregulated and disease is reduced [\[104\]](#CIT0104). Similar to schistosomiasis, in AHR, CCL5 has been shown to modulate cytokine production, inducing a shift from T~h~2- to T~h~1-response [\[99\]](#CIT0099). This mechanism was exploited by Kline *et al.*, where administration of CpG with the allergen reduced AHR and airway eosinophilia, due to an increase in CCL5 expression that suppressed eotaxin production [\[109\]](#CIT0109).

The deleterious influence of RSV infection on airway allergy was confirmed by John and colleagues [\[110\]](#CIT0110) and linked to the production of CCL5, which exacerbates AHR during RSV infection per se. The adoptive transfer of CD8^+^ T cells from RSV-infected mice into allergen-sensitized mice induced AHR in the sensitized mice, which suggests that CD8^+^ T lymphocytes could be the source of CCL5 in this context [\[111\]](#CIT0111). These observations are supported by previous reports on the release of CCL5 by cytotoxic T lymphocytes during viral infection [\[53\]](#CIT0053), bringing mitigating evidence that RSV infection, through the release of chemokines (i.e., CCL5), may play a significant role in enhancing lung inflammation after allergic challenge.

Asthma is a complex condition, and there is much evidence suggesting that CCL5 is expressed in patients with disease and it correlates with disease severity [\[112\]](#CIT0112). Moreover, preclinical studies suggest that CCL5 and its receptors may contribute to disease pathogenesis [\[104\]](#CIT0104). Certain viruses, such as RSV, may worsen experimental allergic airway inflammation and blockade of CCL5 may also prevent exacerbation under these conditions. Therefore, targeting CCL5 in the context of human asthma could be of potential therapeutic interest. Nevertheless, there are some reports suggesting that CCL5 may drive immunoregulatory mechanisms which decrease airway hyperreactivity [\[110\]](#CIT0110).

5.. Atherosclerosis {#S0005}
===================

The role of CCL5 in atherosclerosis has been extensively addressed in several studies in the past 15 years [\[113\]](#CIT0113). The expression of CCL5 is detected in atherosclerotic plaques and in monocyte/macrophages, and is regulated by the Rel proteins p50 and p65. Moreover, the Kruppel-like factor 13 (KLF13), originally designated *RANTES factor of late activated T lymphocytes-1*, has been recently identified as a new transcription factor that regulates the expression of CCL5 in CD4^+^ T cells [\[114\]](#CIT0114). In smooth muscle cells (SMCs), the expression of CCL5 is controlled by the transcriptional regulator Y-box binding protein-1 (YB-1) [\[115\]](#CIT0115). It has been shown that the overexpression of YB-1 in arterial SMCs greatly increased CCL5 transcriptional activity, eventually leading to CCL5-mediated monocyte recruitment. CCR1 and CCR5 are expressed on cell types that participate in atherosclerosis (i.e., monocytes/macrophages, T lymphocytes), and mediate CCL5-dependent arrest and transendothelial diapedesis, resulting in full transmigration into the inflamed tissue. These receptors have also been implicated in the detrimental effects caused by emigrated cells at atherosclerotic lesion sites [\[116\]](#CIT0116).

The blockade of CCL5 receptors has distinct roles on atherosclerosis. Genetic ablation of *ccr5* reduced the extent of atherosclerotic lesions induced by diet, and the late response, leading to a more stable plaque, reduced mononuclear infiltration and inducing a T~h~1-biased immune response. In contrast, the lack of CCR1 enhanced atherosclerotic plaque development and exacerbated local accumulation of T cells [\[117\]](#CIT0117). In a model of arterial wire injury in ApoE^--/--^ mice, CCR5 deficiency protected against neointima formation, which was attributed to an upregulation of IL-10 in neointimal SMCs. In this model, CCR1 deficiency did not affect neointimal area or cell accumulation, but led to an increase in IFN-γ [\[113,118\]](#CIT0113 CIT0118). Separately, knock-down of YB-1, which reduces CCL5 expression in carotid arteries, led to a significant reduction in neointima formation and macrophage accumulation after injury. The protection induced by YB-1 knockdown was not observed in Apoe^--/--^, CCR5^--/--^ or after treatment with Met-RANTES, indicating that the effects of CCL5 are dependent from CCR5 and CCR1 activation [\[115\]](#CIT0115). CCL5 is not only expressed within the atherosclerotic plaque, but platelets also represent an important source of CCL5 under pathological and nonpathological vascular conditions [\[119\]](#CIT0119). In mice, platelets have been shown to exacerbate atherogenesis through deposition of CCL5/CXCL4 heterodimers, triggering monocyte arrest on inflamed endothelium. Treatment with specific inhibitors of CCL5/CXCL4 interaction attenuates monocyte recruitment and reduces atherosclerosis without compromising other aspects of the immune response [\[120\]](#CIT0120). In accordance, curative treatment with \[^44^AANA^47^\]-RANTES, which disrupts CCL5 interactions with GAGs, limited atherosclerotic plaque formation and increased plaque stability in LDLr^--/--^ mice, indicating the protective effect of CCL5 blockade in atherosclerosis [\[121\]](#CIT0121).

Akin to asthma, there is good evidence that CCL5 is expressed and may play a role in human atherosclerosis. Experimental studies have mostly focused on the CCL5 receptors and their role in driving disease is not straight forward and may be opposite. Studies targeting CCL5 with modified proteins (e.g., \[^44^AANA^47^\]-RANTES) do suggest that CCL5 plays a deleterious role in experimental atherosclerosis. Whether this will translate into clinical benefits in humans is not known at present.

6.. Angiogenesis and cancer {#S0006}
===========================

CCL5 is associated with chronic inflammation and may play a direct role in angiogenesis and in other angiogenesis-dependent processes, such as the progression of some tumors. The latter effects could be due to CCL5-mediated leukocyte and nonleukocyte recruitment and activation. Angiogenesis is characterized by the sprouting of new vessels from preexisting activated endothelial cells, which migrates and proliferates to form new vessels. These events will help to form anastomic connections between newly formed vessels, finally splitting into arterioles and capillaries [\[122\]](#CIT0122). In homeostasis, angiogenesis participates in embryogenesis and organ development, as well as in tissue remodeling under pathological conditions [\[122\]](#CIT0122).

Chemokines have been shown to contribute to angiogenesis by balancing the stimulation or inhibition of endothelial cell proliferation and branching. The main chemokines studied in angiogenesis are the CXC chemokines, but CC chemokines have also been described to contribute to this process. The involvement of CCL5 in the context of inflammatory angiogenesis has been previously shown. For example, in a model of sponge-induced inflammatory angiogenesis CCL5 had antiangiogenic activity [\[123\]](#CIT0123). CCL5 expression was detected early after sponge implantation, but levels significantly increased thereafter. Exogenous administration of CCL5 reduced angiogenesis in WT mice via CCR5, as CCL5 had no effect in CCR5^−/−^ mice. In accordance with these observations, treatment of WT mice with Met-RANTES prevented neutrophil and macrophage accumulation and enhanced sponge vascularization [\[123\]](#CIT0123).

In contrast, several studies suggest that CCL5 may be considered as a proangiogenic factor. CCL5 oligomerization and binding to GAGs are essential to induce angiogenic effects through CCR1 and CCR5 [\[124\]](#CIT0124). Indeed, CCR5^−/−^ mice had reduced corneal neovascularization, which correlated with reduced expression of VEGF, suggesting that CCR5 is a key player in the process of corneal neovascularization [\[125\]](#CIT0125). Thus, CCL5 could be associated to VEGF in the context of angiogenesis, and this is supported by *in vitro* studies showing the promotion of endothelial cell migration, spreading and neo-vessel formation by CCL5 [\[124\]](#CIT0124). Moreover, Met-RANTES reduced endothelial progenitor cell homing to activated (glomerular) endothelium *in vitro* and *in vivo* [\[126\]](#CIT0126) in a rat model of glomerulonephritis.

Tumors are known to recruit blood vessels to continue growth and to promote potential routes for metastasis [\[122\]](#CIT0122). CCL5 is expressed in a variety of cancer and metastatic processes, such as breast carcinoma [\[127\]](#CIT0127), melanoma [\[128\]](#CIT0128) and papillary thyroid carcinoma [\[129\]](#CIT0129). For instance, chemokines expressed by malignant and stromal cells contribute to the extent and phenotype of the tumor-associated leukocytes, to angiogenesis and to the generation of the fibroblast stroma. In fact, CCL5 recruits monocyte and macrophage precursors to the tumor microenvironment and positively correlates with the extent of myeloid cell infiltrate and tumor progression [\[130\]](#CIT0130). Tumors that expressed low levels of CCL5 exhibited a decrease in growth rate *in vivo*, which is associated to a greater tumor-specific T cell response. Conversely, tumors expressing high levels of CCL5 induce a reduced T cell response and upregulates matrix metalloproteinase-9 transcripts, which contributes to angiogenesis. These observations indicate that tumor-derived CCL5 facilitate tumor growth by inhibiting T cell responses and enhancing angiogenesis [\[131\]](#CIT0131). Chemokines may also provide survival signals for malignant cells, since these cells gain functional chemokine receptors that may contribute to metastatic activity. Malignant cells acquire leukocyte-like properties and are able to respond to chemokine gradients at sites of metastasis [\[132\]](#CIT0132). CCL5 is secreted by senescent aged fibroblasts, induces proliferation of prostate epithelial cells and induces expression of genes related to angiogenesis [\[133\]](#CIT0133). The interaction between cancer and its local microenvironment can determine properties of growth and metastasis. Osteopontin promotes CCL5-mesenchymal stromal cell (MSC)-mediated breast cancer metastasis, by increasing MSC migration to metastatic sites in lung and liver, promoting tumor progression via the transformation of MSC into cancer-associated fibroblasts [\[134\]](#CIT0134). Collectively, these data suggested that CCL5 plays a central role in cancer progression, by affecting tumor directly and by controlling leukocyte recruitment and angiogenesis. Thus, therapies that block CCL5 or its receptors could potentially help the treatment of cancer and metastasis, given that its blockade reduces tumor angiogenesis and not the opposite.

7.. Fibrosis and transplant rejection {#S0007}
=====================================

Fibrosis is commonly a result of chronic inflammation. Fibrosis is defined by the excessive collagen accumulation in and around inflamed or damaged tissue, which can lead to permanent scarring and organ malfunction, and ultimately death. It is related to major pathological features of different chronic autoimmune diseases [\[135\]](#CIT0135). In fact, some fibrogenic diseases are associated to CCL5 expression or CCR5 activation. In patients with localized scleroderma, a significant increase in mRNA for CCL5 was found in the lesions [\[136\]](#CIT0136). CCL5 was localized in the cytoplasm in CD68^+^ alveolar macrophages in sarcoidosis, and in both alveolar macrophages and eosinophils in fibrosing alveolitis [\[137\]](#CIT0137). Also, CCL5 expression was associated with increasing numbers of CD45RO^+^ lymphocytes in the bronchoalveolar lavage, indicating that CCL5 may mediate T-lymphocyte influx. Collectively, CCL5 is important for fibrosis in diffuse lung disease and the cell sources of CCL5 are alveolar macrophages, macrophages and eosinophils [\[137\]](#CIT0137). Separately, in a mouse model of lung fibrosis induced by bleomycin, the CCL3-CCR5 axis, but not CCL5-CCR5 axis, was associated to the presence of intrapulmonary fibrocytes and collagen accumulation, which is also linked to high numbers of TGFβ^+^ macrophages and myofibroblasts [\[138\]](#CIT0138).

The antagonist Met-RANTES was used to evaluate the role of CCL5 in hepatic fibrosis induced by carbon tetrachloride. Met-RANTES blocked the effects of hematopoietic cells-derived CCL5 on cultured stellate cell, inhibiting migration, proliferation, chemokine secretion and collagen deposition. Importantly, *in vivo* administration of Met-RANTES ameliorated liver fibrosis in mice and was able to accelerate fibrosis regression, suggesting that CCL5-receptors blockade reduce inflammation and may be used to treat liver fibrosis [\[139\]](#CIT0139). Met-RANTES also diminished early infiltration and activation of mononuclear cells in kidney fibrosis and chronic allograft nephropathy, with an important reduction in the expression of TGFβ and PDGF-B [\[140\]](#CIT0140). The sole blockade of CCR1, instead of CCR1/CCR5 blockade caused by Met-RANTES treatment, can also be employed to prevent chronic inflammation and tissue remodeling. CCR1^−/−^ mice are more resistant to myocardial infarction, presenting reduced recruitment of proinflammatory cells early after the infarction, associated with increased tissue healing [\[141\]](#CIT0141).

CCL5 has also been implicated in organ transplant rejection, in which CCL5 would mediate the recruitment of mononuclear cells that destroy the transplanted tissue and contributes to transplant dysfunction or loss. Treatment with BX471, a small-molecule antagonist of CCR1, prolonged allograft rejection in a heart transplant model in rats. This improvement in heart transplant survival was attributed to reduced endothelial damage, as CCR1 blockade reduced CCL5-mediated monocyte arrest on the transplanted heart endothelium [\[30\]](#CIT0030). In another study, BX 471 reduced the progression of chronic renal allograft damage, also through reduction of mononuclear cell recruitment to the renal tissue. Decreased numbers of mononuclear cells led to reductions in collagen deposition, TGFβ1 levels and α-SMA+ interstitial myofibroblasts accumulation in the renal allograft [\[142\]](#CIT0142).

These data suggest that blockade of CCL5 receptors may represent a therapeutic opportunity in fibrosis and transplant rejection, since CCR5/CCR1 blockade effectively reduces leukocyte recruitment and prevents tissue damage and remodeling. Whether blockade of CCL5 would achieve similar results needs to be determined.

8.. Expert opinion {#S0008}
==================

There are many epidemiological and clinical studies in several human diseases demonstrating the expression of CCL5 and correlation with indices of disease activity. These data are compounded by many preclinical studies showing the functional role of CCL5 and its receptors. Overall, there is good evidence that CCL5 has unique roles in driving recruitment of leukocytes, angiogenesis and fibrosis in various models of chronic inflammation. Therefore, blockade of CCL5 and its receptors may be useful in decreasing inflammatory cell influx and fibrosis in chronic diseases. Possible targets for CCL5-based drugs include chronic lung diseases, such as asthma and pulmonary fibrosis, liver fibrosis and atherosclerosis. There is also good evidence that CCL5 may play a role in driving angiogenesis and tumor growth, suggesting CCL5-based therapies may be useful as adjunct therapy of certain solid tumors. Moreover, there are good data suggesting that CCL5 plays relevant role in the immune response against certain infections, especially viral infections. This is against the notion that the chemokine system is redundant or promiscuous. There are clearly distinct roles played by chemokines and their receptors which could eventually be translated into novel therapies.

Genetic functional deficiency of CCR5 and blockade of CCR5 with antagonists are clearly beneficial in the context of HIV infection. The role of CCL5 and its receptors in the context of other viral diseases is much less clear. Whereas CCL5 may have host-protective effects in the early phases of viral infections, it may also contribute to disease pathogenesis by driving influx of cells which may damage tissues. This dual effect of CCL5 makes it difficult to target this chemokine in human diseases, as it is difficult to make clear distinction between phases where there is only viral replication or immunopathology. It may be argued that targeting CCL5 could be added to available antiviral drugs. This is indeed a possibility for drug development but faces the issue of timely recognition of the etiology of viral infections in the clinical setting. We are particularly interested in the role played by CCL5 in diseases caused by flaviviruses, the viruses that compose the Flavivirus genre. Infection with these pathogens can cause an intense inflammatory response, which may manifest as encephalitis or as a hemorrhagic fever, depending on viral tropism. CCL5 is a component of this intense inflammatory response and is likely to contribute to disease in later phases of infection. St. Louis encephalitis and dengue are examples of flaviviral infections in which the precise role of CCL5 still needs to be determined.

[Table 2](#T0002) lists clinical trials which target CCL5 and its receptors in human diseases [\[143\]](#CIT0143). As can be seen, the majority of ongoing clinical trials involves antagonism of CCL5 receptors and not targeting of CCL5 itself. Therefore, the exact function of this chemokine in the context of human disease still remains to be determined. This is not a minor point as CCL5 may bind to multiple receptors and the targeted receptors may be activated by multiple chemokines ([Figure 1](#F0001)). Clearly, nonredundant functions of any chemokine or receptor will be only uncovered when a particular molecule is targeted in humans. Antagonists, such as \[^44^ANAA^47^\]-RANTES, \[E66A\]-RANTES and MKEY ([Table 1](#T0001)), prevent binding of CCL5 to GAGs or its oligomerization. As these molecules compete directly with CCL5 for its functions and have a mechanism of action distinct from receptor antagonism, they may provide further insight into the biology of CCL5 in human diseases. However, to the best of our knowledge, these modified molecules have not been taken into humans yet. Only recently, an antibody which targets CCL5 (NovImmune SA, NI-0701, [Table 2](#T0002)) has passed Phase I clinical studies and have become available for further human experimentation. It will be instrumental in determining the exact role of CCL5 in human diseases.
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###### 

**Clinical trials targeting CCL5/RANTES and receptors in human disease.**

  **Compound name**                        **Strategy**                                                                       **Company/Sponsor**                                                                                                                                                  **Disease of interest**              **Official title of clinical studies**                                                                                                                                                                                                                                                                             **Phase and status**          **Trial number**
  ---------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------- ------------------
  Cenicriviroc                             CCR2 and CCR5 Antagonist                                                           Tobira Therapeutics, Inc.                                                                                                                                            HIV/AIDS                             A Phase IIb randomized, double-blind, double-dummy trial of 100 or 200 mg once-daily doses of cenicriviroc (CVC, TBR 652) or once-daily EFV, each with Open-Label FTC/TDF, in HIV 1-Infected, antiretroviral treatment-Naïve, adult patients with only CCR5-Tropic virus                                           Phase II: ongoing             NCT01338883
  GW873140                                 CCR5 Antagonist                                                                    GlaxoSmithKline                                                                                                                                                      HIV/AIDS                             A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400 mg BID in combination with a ritonavir-containing optimized background therapy regimen versus placebo plus OBT over 48 weeks.                                      Phase III: terminated         NCT00297076
  INCB009471                               CCR5 Antagonist                                                                    Incyte Corp.                                                                                                                                                         HIV/AIDS                             A randomized, double-blind, placebo-controlled study exploring the safety, tolerability, PK & virological effect of once daily Oral dosing of INCB009471 as monotherapy for 14 days in ARV-naïve/Limited ARV-experienced, HIV-1 infected patients                                                                  Phase II: completed           NCT00393120
  TBR 652                                  CCR5 Antagonist                                                                    Tobira Therapeutics, Inc.                                                                                                                                            HIV/AIDS                             A proof of concept, multiple dose-escalating study to evaluate the antiviral activity, safety, and pharmacokinetics of the CCR5 antagonist TBR 652 in HIV 1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients                                                                         Phase I and II: completed     NCT01092104
  Maraviroc                                CCR5 Antagonist                                                                    ViiV Healthcare/Pfizer                                                                                                                                               HIV/AIDS                             Drug use investigation for HIV infection patients of maraviroc (regulatory post marketing commitment plan)                                                                                                                                                                                                         Phase IV: Ongoing             NCT00864474
  Maraviroc                                CCR5 Antagonist                                                                    University of California, San Francisco/National Heart, Lung, and Blood Institute (NHLBI)/Pfizer                                                                     HIV/AIDS                             Effect of maraviroc on endothelial function in HIV-infected patients                                                                                                                                                                                                                                               Phase III: Ongoing            NCT00844519
  Maraviroc                                CCR5 Antagonist                                                                    Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal/Pfizer                                                                            HIV/AIDS                             Pilot study of the effect of a CCR5 coreceptor antagonist on the latency and reservoir of HIV-1 in patients taking highly active antiretroviral therapy                                                                                                                                                            Phase II: ongoing             NCT00795444
  Maraviroc                                CCR5 Antagonist                                                                    ViiV Healthcare/Pfizer                                                                                                                                               HIV/AIDS                             A multicenter, randomized, blinded, placebo-controlled study to evaluate the safety of maraviroc in combination with other antiretroviral agents in HIV-1-infected subjects co-infected with Hepatitis C and/or Hepatitis B virus                                                                                  Phase IV: ongoing             NCT01327547
  Maraviroc                                CCR5 Antagonist                                                                    University of California, San Francisco/Pfizer/ViiV Healthcare                                                                                                       HIV/AIDS Kaposi Sarcoma              effects of maraviroc on HIV-related kaposi\'s sarcoma                                                                                                                                                                                                                                                              Phase III: study recruiting   NCT01276236
  Maraviroc                                CCR5 Antagonist                                                                    University of Pennsylvania/Pfizer                                                                                                                                    GVHD\\⊂ Transplantation              Safety and efficacy of maraviroc, a CCR5-inhibitor in prophylaxis of graft-Versus-host disease in patients undergoing non-myeloablative allogeneic stem-cell transplantation                                                                                                                                       Phase I and II: completed     NCT00948753
  Maraviroc                                CCR5 Antagonist                                                                    National Center for Tumor Diseases, Heidelberg/University Hospital Heidelberg/Pfizer                                                                                 Colorectal cancer/Liver metastasis   Treatment of advanced colorectal cancer patients with hepatic liver metastases using the CCR5-antagonist maraviroc (phase I maracon trial)                                                                                                                                                                         Phase I: recruiting           NCT01736813
  Maraviroc                                CCR5 Antagonist                                                                    Abramson Cancer Center of the University of Pennsylvania/Pfizer                                                                                                      GVHD/Cancer                          A phase II study to assess the efficacy of maraviroc, a CCR5-antagonist in prophylaxis of graft-versus-host disease in patients with hematologic malignancies undergoing reduced-intensity allogeneic stem-cell transplantation from unrelated donors                                                              Phase II: recruiting          NCT01785810
  Maraviroc                                CCR5 Antagonist                                                                    S.F.L. van Lelyveld, UMC Utrecht/Pfizer                                                                                                                              HIV/Cardiovascular disease           Maraviroc abacavir study - effect on endothelial recovery                                                                                                                                                                                                                                                          Phase IV: recruiting          NCT01389063
  GSK706769                                CCR5 Antagonist                                                                    GlaxoSmithKline                                                                                                                                                      Rheumatoid arthritis                 A randomized, double-blind, placebo-controlled, parallel group study to investigate the ability of GSK706769 to maintain clinical remission after withdrawal of enbrel in patients with rheumatoid arthritis                                                                                                       Phase II:                     NCT00979771
  Vicriviroc, SCH 417690                   CCR5 Antagonist                                                                    Schering-Plough                                                                                                                                                      HIV/AIDS                             Vicriviroc in combination treatment with an optimized ART regimen in treatment-experienced subjects with R5/X4 HIV infection (VICTOR-E2; protocol no. P05057)                                                                                                                                                      Phase II: completed           NCT00551330
  NI-0701                                  Antibody against CCL5                                                              NovImmune SA                                                                                                                                                         Chemokine blockade                   A first in man randomized placebo controlled study of single ascending intravenous doses of NI-0701 in healthy volunteers                                                                                                                                                                                          Phase I: completed            NCT01255501
  PRO 140                                  Antibody against CCR5                                                              Progenics Pharmaceuticals, Inc.                                                                                                                                      HIV/AIDS                             A Phase IIa, randomized, double-blind, placebo controlled study of PRO 140 by subcutaneous administration in adult subjects with Human Immunodeficiency virus Type 1 Infection                                                                                                                                     Phase II: Completed           NCT00642707
  CCR5mAb004                               Antibody against CCR5                                                              Human Genome Sciences, Inc./GlaxoSmithKline                                                                                                                          HIV/AIDS                             A Phase I, randomized, placebo-controlled, single-injection, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Ccr5mab004 (human monoclonal Igg4 antibody to Ccr5) in HIV-1 seropositive individuals who are not receiving concurrent antiretroviral therapy   Phase I: Completed            NCT00114699
  HGS1025                                  Antibody against CCR5                                                              Human Genome Sciences, Inc./GlaxoSmithKline                                                                                                                          Ulcerative Colitis                   A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics and Safety of HGS1025, a Human Monoclonal Anti-CCR5 Antibody, in Subjects With Ulcerative Colitis                                                                                                                  Phase I:                      NCT01434576
  CCX 354-C                                CCR1 Antagonist                                                                    ChemoCentryx                                                                                                                                                         Rheumatoid arthritis                 A Randomized, double-blind, placebo-controlled, phase I/II study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis                                                                                                                                                             Phase I and II: completed     NCT01027728
  BAY86-5047, ZK811752, SH T 04268H        CCR1 Antagonist                                                                    Bayer                                                                                                                                                                Endometriosis                        A Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety, tolerability and efficacy of the CCR1 antagonist ZK 811752, given orally in a dose of 600 mg three times daily, for the treatment of endometriosis over 12 weeks                                         Phase II: Completed           NCT00185341
  AZD4818                                  CCR1 Antagonist                                                                    AstraZeneca                                                                                                                                                          COPD                                 A 4-week double-blind, placebo-controlled, randomized, parallel group phase IIa study to assess the tolerability/safety and efficacy of inhaled AZD4818 in patients with moderate to severe chronic obstructive pulmonary disease                                                                                  Phase II: Completed           NCT00629239
  CP-481,715                               CCR1 Antagonist                                                                    Pfizer                                                                                                                                                               Skin allergy                         Placebo-controlled, randomized, parallel group, multiple-dose study to evaluate the effects of CP-481,715 on clinical response and cellular infiltration following contact allergen challenge to the skin of nickel allergic subjects.                                                                             Phase I: Completed            NCT00141180
  GW766944                                 CCR3 Antagonist                                                                    GlaxoSmithKline                                                                                                                                                      Asthma/Sputum eosinophilia           A Randomized, double-blind, placebo-controlled, parallel group study to compare GW766944 (an oral CCR3 receptor antagonist) versus placebo in patients with asthma and sputum eosinophilia                                                                                                                         Phase II: Completed           NCT01160224
  SB-728                                   Zinc Finger Nuclease modified T cells                                              University of Pennsylvania/Sangamo Biosciences                                                                                                                       HIV/AIDS                             A Phase I study of autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases SB-728 in HIV-infected patients                                                                                                                                                                               Phase I: completed            NCT00842634
  Lentivirus vector rHIV7-shI-TAR-CCR5RZ   Lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells   City of Hope Medical Center/National Cancer Institute (NCI)                                                                                                          HIV/Cancer                           A pilot study of safety and feasibility of stem cell therapy for aids lymphoma using stem cells rreated with a lentivirus vector-encoding multiple anti-HIV RNAs                                                                                                                                                   Phase I: ongoing              NCT00569985
  CCR5delta32 hematopoietic stem cell      HLA-compatible hematopoietic stem cell from CCR5delta32homozygotes donors          Medical College of Wisconsin/National Heart, Lung, and Blood Institute (NHLBI)/National Cancer Institute (NCI)/Blood and Marrow Transplant Clinical Trials Network   HIV/Cancer                           Allogeneic hematopoietic cell transplant for hematological cancers and myelodysplastic syndromes in HIV-infected individuals                                                                                                                                                                                       Phase II: recruiting          NCT01410344

Description of the clinical trials targeting CCL5/RANTES and its receptors in human disease [\[139\]](#CIT0139).

AIDS: Acquired immunodeficiency syndrome; COPD: Chronic obstructive pulmonary disease; GVHD: Graft versus host disease; HIV: Human immunodeficiency virus.

###### 

Article highlights.

-   CCL5 is a key proinflammatory chemokine.

-   CCL5 can contribute to protection in certain infectious diseases.

-   Strong experimental evidence suggests that CCL5 blockade can prevent immunopathology.

-   Current experimental tools and clinical trials have focused on chemokine receptor antagonism.

-   New tools to block CCL5 directly must be developed in order to precisely assess CCL5 biologic functions.
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